
DMPI
Healthcare · Biotechnology · $15.4M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2020
EPS trend, 90 days to now · -8.3% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2020 | Time not confirmed | -0.09 | -1.33 | -1377.8% |
| Sep 8, 2020 | Time not confirmed | -0.13 | -0.33 | -153.8% |
| May 13, 2020 | Time not confirmed | -0.12 | -0.17 | -41.7% |
| Feb 13, 2020 | Time not confirmed | -0.17 | -0.15 | +11.8% |
| Nov 13, 2019 | Time not confirmed | — | -0.21 | — |
| Sep 9, 2019 | Time not confirmed | -0.61 | -0.89 | -45.9% |
| May 14, 2019 | Time not confirmed | — | -0.67 | — |
| Feb 11, 2019 | Time not confirmed | — | -0.75 | — |
| Nov 13, 2018 | Time not confirmed | — | -0.88 | — |
| Sep 24, 2018 | Time not confirmed | -1.10 | -1.00 | +9.1% |
| May 15, 2018 | Time not confirmed | -1.00 | -1.30 | -30.0% |
| Feb 14, 2018 | Time not confirmed | -1.50 | -1.40 | +6.7% |
DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. Its product candidate is VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung…